Trial Profile
A Single-arm, Open-label Study of Ad-RTS-hIL-12 + Veledimex Following First-, Second-, or Third-Line Standard Treatment in Subjects With Locally Advanced or Metastatic Breast Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 14 Feb 2022
Price :
$35
*
At a glance
- Drugs INXN 2001 (Primary) ; Veledimex
- Indications Adenocarcinoma; Advanced breast cancer
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics; ZIOPHARM Oncology
- 20 Apr 2021 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Results assessing anti-tumor immunity via intratumoral regulated platform ad-RTS-hIL-12 in heavily pretreated patients with metastatic breast cancer or recurrent glioblastoma (NCT02026271; NCT02423902), presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 13 Feb 2017 Status changed from recruiting to active, no longer recruiting.